Many FDA approved cancer drugs have offered patients only marginal benefits, with no evidence that they improve survival or quality of life
Diana Zuckerman, Cancer Prevention and Treatment Fund President, comments on how the FDA and high drug prices could be negatively affected by the hiring freeze, despite President Donald Trump emphasizing the need for lowering “astronomical” drug prices to pharmaceutical executives.
Christmas came early for the pharmaceutical industry when Congress passed the 21st Century Cures Act. Though lauded by liberals for funding medical research, its real impact will be elsewhere, including encouraging FDA to approve cancer drugs and other “cures” that don’t work.
December 8, 2016 – Against all expert opinion, Jim O’Neill, “a snake oil salesman” with no medical background, is rumored to head the Food and Drug Administration (FDA) in 2017
December 7, 2016 – the 21st Century Cures Act, the most expensive and far-reaching health reform bill since the ACA, has just been passed by Congress
Star Tribune, November 10, 2016 – CPTF President Diana Zuckerman said the Infuse Bone Graft is “contraindicated” for children. But the FDA’s 2015 warning didn’t ban the product in kids because some children have such significant bone defects or such rare bone disorders that they would be willing to accept the risks.